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INTRODUCTION
Gastric cancer is the fourth most common cancer in the world,
and the second most common cause of cancer deaths in Japan
(1, 2). The treatment strategy for curable gastric cancer is ade-
quate local control. The standard treatment for curable gastric
cancer is gastrectomy with D2 lymphadectomy (3). However, 4% to
14% of patients with primary gastric cancer have liver metastasis.
Gastric cancer liver metastasis (GLM) is a fatal disease and the
prognosis is dismal. In Japan, the first line treatment for GLM is
systemic chemotherapy (4-6). However, the effect of chemother-
apy is unsatisfactory and limited.
In contrast to GLM, the feasibility and oncologic outcome of
hepatic resection for colorectal cancer liver metastasis has been
established. The 5-year survival rate of patients after hepatic resec-
tion of colo-rectal cancer liver metastasis is 40% to 58% (7, 8). Com-
plete surgical resection of the primary lesion and the liver metastasis
appears to be the only chance for cure. However, in gastric cancer,
surgical indication for GLM remains controversial. Patients with
GLM often have locally advanced disease, peritoneal dissemina-
tion, lymph node metastasis, and distant metastasis. Although in
some reports a feasible outcome of hepatic resection for GLM has
been presented, hepatic resection for GLM is rarely indicated.
There have been few reports about hepatic resection for GLM and a
reported 5-year survival rate after hepatic resection for GLM is
18% to 42% (9-15).
The aim of this study is to clarify the long-term effect of hepatic
resection for GLM.
METHODOLOGY
Ten patients in this study underwent hepatic resection for gastric
cancer liver metastasis at Tokushima University Hospital between
2001 and 2013. These 10 patients comprised 9 men and 1 woman
with a median age of 71.7 years (a range of 50 to 81 years). Six
patients underwent synchronous hepatic resection and gastrec-
tomy, and the remaining 4 patients underwent metachronous
hepatic resection. Six patients had solitary liver metastasis, and 4
patients had multiple liver metastasis. The median maximum
tumor size was 23.5 mm. Pre-operative chemotherapy was ad-
ministered in 2 cases (20%). That is, S-1 in 1 case and Docetaxel
plus Cisplatin plus S-1 in 1 case. Five patients underwent hepatic
lobectomy ; 2 patients underwent hepatic segmentectomy, and 5
patients underwent partial resection of the liver. Postoperative ad-
junct chemotherapy was administered in six (6) cases (60%).
That is, S-1 in 1 case ; S-1 plus Cisplatin in 1 case ; S-1 plus CPT-11
in 2 cases ; and UFT in 2 cases. The median follow-up period was
12.4 months (the range being between 0.5 months and 50 months).
The patients’ characteristics are shown in Table 1. No patient un-
derwent repeat hepatic resection.
STATISTICAL ANALYSIS
All statistical analysis hasbeen calculated through Stat View sta-
tistical software (Stat View 5.0, SAS Institute, Cary, NC). The
clinico-pathological variables have been analyzed with the chi -
square test and Mann-Whitney U test. Survival curves have been
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calculated using the Kaplan-Meier method and compared using
the Wilcoxon test. Statistical significance has been defined as p
0.05.
RESULTS
The actual 1- year and 3-year overall survival rates for the pa-
tients who underwent synchronous hepatic resection and gastrec-
tomy and those who underwent metachronous hepatic resection
are 88.9% and 17.8%, respectively. The median survival time is 21.5
months (Figure 1) and the 1-year recurrence free survival rate is
20.0%. The median recurrence free survival rate is 4.7 months
(Figure. 2). There has been no postoperative mortality, and 1 pa-
tient has had postoperative bile leakage. Six patients have had re-
currence in the liver, and 1 patient has had recurrence in the brain
after hepatic resection.
Uni -variate analysis has presented no significant risk factor in
overall survival in age ; serosal invasion of primary gastric cancer ;
timing of hepatic resection ; type of hepatic resection ; pre-opera-
tive chemotherapy ; post-operative chemotherapy ; maximum
tumor size of GLM ; and the number of GLM. Regarding post-
operative recurrence after hepatic resection, synchronous hepatic
resection tended to be a recurrence factor (p=0.08). The 1-year
recurrence free survival rate is 41.7% in metachronous hepatic re-
section, and 27.8% in synchronous hepatic resection, respectively.
No significant difference in recurrence free survival has been
found in age ; serosal invasion of primary gastric cancer ; type of
hepatic resection ; preoperative chemotherapy ; postoperative
chemotherapy ; maximum tumor size of GLM ; and the number of
GLM.
DISCUSSION
The discussion focuses on the outcome of hepatic resection for
GLM. The actual 1 to 3-year overall survival rates for patients who
underwent synchronous hepatic resection and gastrectomy and
those who underwent metachronous hepatic resection are 88.9%
and 17.8%, respectively and the median survival time is 21.5 months.
Synchronous hepatic resection tends to be a recurrence factor.
There have been several retrospective reports from Japan of
small numbers of patients undergoing hepatic resection for GLM.
The 5-year survival rate is 18% to 42% and the median survival time
after surgery is reported as 12 months to 34 months (9-15). Overall
survival time and median survival time of our study is comparable to
other trial. According to previous reports, the prognostic factors
after hepatic resection for GLM are serosal invasion of the primary
gastric cancer ; lymph node metastasis ; the number of hepatic me-
tastasis ; the surgical margin ; the maximum diameter of hepatic
metastasis ; and the timing of hepatic resection. Recently, Takemura
et al. demonstrated that the overall 1 -year, 3 -year and 5-year
Table 1 Patients’ characteristic
Characteristic
Age 71.7 (50 -81)
Sex (male/ female) 9/1
Serosal Invasion primary gastric cancer (Yes/ No) 2/8
Timing of hepatectomy (Synchronous/ Metachronous) 6/4
Type of hepatic resection (lobectomy/segmentectomy/partial resection) 3/2/5
Preoperative Chemotherapy (Yes/ No) 3/7
Postoperative chemotherapy (Yes/ No) 8/2
Maximum tumor size (mm) 23.5 (10 -74)
Number of liver metastasis (solitary/ multiple) 6/4
Follow up period (m) 12.4 (0.5 -50)
Figure 1.
Overall survival after hepatic resection for gastric liver metastasis
Figure 2.
Recurrence free survival after hepatic resection for gastric liver metastasis
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Table 3 Univariate analysis for recurrent free survival
Characteristic No of patients 1 -yr RFS(%) P value
All patients 10 71.1
Age 0.28
70 5 60.0
70 5 40.0
Serosal Invasion 0.59
Positive 2 100
Negative 8 43.8
Timing of hepatic resection 0.08
Synchronous 6 27.8
Metachronous 4 41.7
Type of hepatic resection 0.58
Major 5 33.3
Minor 5 60
Preoperative Chemotherapy 0.46
Yes 3 50.0
No 7 51.4
Postoperative chemotherapy NA
Yes 8 50.0
No 2 NA
Maximum tumor size 0.89
25mm 5 40.0
25mm 5 66.7
Number of liver metastasis 0.96
Solitary 6 41.7
Multiple 4 66.7
Table 2 Univariate analysis for overall survival
Characteristic No of patients 1 -yr OS(%) 3-yr OS(%) P value
All patients 10 71.1 17.8
Age 0.87
70 5 66.7 0
70 5 75.0 37.5
Serosal Invasion 0.99
Posirive 2 100 0
Negative 8 85.7 21.4
Timing of hepatic resection 0.79
Synchronous 6 80 40
Metachronous 4 100 0
Type of hepatic resection 0.58
Major 5 100 0
Minor 5 80 20
Preoperative Chemotherapy 0.69
Yes 3 100 0
No 7 85.7 21.4
Postoperative chemotherapy NA
Yes 8 87.5 17.5
No 2 NA NA
Maximum tumor size 0.74
25mm 5 80.0 26.7
25mm 5 100 0
Number of liver metastasis 0.27
Solitary 6 80 26.7
Multiple 4 100 0
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survival rates after hepatic resection for GLM are 84%, 50% and
37% in the selected patients, respectively. They also found that
GLM patients with a maximum diameter of hepatic metastasis of 5
cm and negative serosal invasion of primary gastric cancer were
good candidates for hepatic resection (14). Sakamoto et al. recom-
mends hepatic resection for GLM with unilobar liver metastasis of 4
cm or less tumor size (15).
In the last two decades, chemotherapy has improved in its use in
gastric cancer. We can now use several chemo-therapeutic agents
in the treatment of gastric cancer. In Japan, the combination of S-1
and Cisplatin is standard treatment for advanced gastric cancer. As
second line or third line treatment regimens, patients have received
Ramucirumab, Nab-paclitaxel, Paclitaxel, Docetaxel, Irinotecan,
Trastuzumab, Capecitabine and others. However, chemotherapy
is not a curative treatment, and the effect is limited. Trials under-
taken by Spirits show that the median survival time using S-1 and
Cisplatin chemotherapy is 13.0 months (16). If hepatic resection
contributes to local control of metastatic gastric cancer, treatment
option would be widened.
Radio- frequency ablation (RFA) and trans-arterial chemo-em-
bolization (TACE) are standard treatment options in hepato-cell-
ular carcinoma as non-surgical treatments. In GLM, only small -
sized retrospective studies or case reports have been presented to
date. Yamakado et al. demonstrated the results of RFA following
hepatic arterial infusion therapy for 7 patients with GLM. RFA was
performed on sixteen (16) liver tumors, resulting in complete
tumor necrosis, and a median survival time of 16.5 months (17).
Hirasawa et al. reported 8 cases of TACE using degradable starch
microspheres for the treatment of GLM (18). The actual 1 year
and 2-year survival rates are 87.5% and 52.5%, respectively and the
median survival time is 36.1 months. These results show that RFA
and TACE may be treatment options for GLM. As this is a retro-
spective study and includes only a small number of patients, a
larger series of prospective randomized control trials are needed to
clarify surgical indications for GLM. We hope that aggressive
surgical resection, combined with systemic chemotherapy, and/or
RFA and TACE, will contribute to patients’ outcomes in future
cases of GLM.
In conclusion, hepatic resection for GLM has an acceptable out-
come and, of the two types of resection considered in this study,
metachrnous hepatic resection tends to have a better outcome than
synchronous hepatic resection for the treatment of GLM. Thus,
surgeons should consider hepatic resection for GLM as a treat-
ment option.
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